Phenoxathiin is a heterocyclic compound containing both an oxygen and a sulfur atom within a tricyclic ring system. It has been studied for its potential applications in various fields, including materials science, organic electronics, and medicinal chemistry. Its synthesis typically involves the condensation of 2-halophenols with 2-halothiophenols under basic conditions. The compound exhibits interesting electrochemical and optical properties, making it a promising candidate for use in organic light-emitting diodes (OLEDs), organic field-effect transistors (OFETs), and other electronic devices. Furthermore, phenoxathiin derivatives have been explored for their biological activity, showing potential as antimicrobial, antifungal, and anticancer agents. The research on phenoxathiin aims to understand its structure-property relationships, explore its potential applications, and develop novel derivatives with improved properties.'
phenoxathiin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9217 |
| CHEMBL ID | 82492 |
| SCHEMBL ID | 7922 |
| MeSH ID | M0186499 |
| Synonym |
|---|
| CHEMBL82492 , |
| smr001224509 |
| MLS002152898 |
| phenoxathiine |
| dibenzooxathiane |
| inchi=1/c12h8os/c1-3-7-11-9(5-1)13-10-6-2-4-8-12(10)14-11/h1-8 |
| NCGC00091342-01 |
| epa pesticide chemical code 064301 |
| caswell no. 651 |
| ccris 4612 |
| brn 0143232 |
| nsc 464 |
| ai3-00037 |
| einecs 205-975-8 |
| dibenzothioxin |
| phenoxathine |
| usaf do-17 |
| nsc464 |
| 262-20-4 |
| wln: t c666 bo isj |
| phenoxathiin |
| nsc-464 |
| 1,4-dibenzothioxine |
| phenoxathrin |
| phenothioxin |
| phenoxthin |
| phenoxathiane |
| SR-01000436114-2 |
| phenoxathiin, 97% |
| AKOS001488864 |
| FT-0652237 |
| HMS1610K10 |
| P1296 |
| bdbm50059293 |
| cid_9217 |
| NCGC00091342-02 |
| 5-19-02-00043 (beilstein handbook reference) |
| unii-bjc51v8xw8 |
| bjc51v8xw8 , |
| dtxcid904937 |
| dtxsid4024937 , |
| cas-262-20-4 |
| tox21_303241 |
| NCGC00256961-01 |
| NCGC00259824-01 |
| tox21_202275 |
| 6-phenoxy-2h-thiopyran;phenoxathiin |
| A818328 |
| CCG-55100 |
| c12h8os |
| RB3009 |
| SCHEMBL7922 |
| rjc 03297 |
| mfcd00046933 |
| GS-5913 |
| sr-01000436114 |
| SR-01000436114-1 |
| J-016326 |
| SY023062 |
| Q25323736 |
| AMY20613 |
| CS-0146166 |
Phenoxathiins are an important class of sulfur-containing heterocycle. Found as the core component in numerous pharmaceutically active agents and materials.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Phenoxathiins are an important class of sulfur-containing heterocycle, found as the core component in numerous pharmaceutically active agents and materials. " | ( Synthesis of phenoxathiins using an iron-catalysed C-H thioarylation. Dodds, AC; Sutherland, A, 2022) | 2.53 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.3548 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 56.2341 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 51.9225 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 89.1251 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 34.3899 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 46.9276 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
| AR protein | Homo sapiens (human) | Potency | 15.9629 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 23.8112 | 0.0002 | 14.3764 | 60.0339 | AID588532; AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 29.6465 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 0.0013 | 0.0008 | 17.5051 | 59.3239 | AID1159527 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 34.9363 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 61.1306 | 0.0002 | 29.3054 | 16,493.5996 | AID743079 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 56.2341 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 54.9410 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 51.1758 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 56.2341 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 28.1838 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 1.9953 | 0.7943 | 21.2757 | 50.1187 | AID624246 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 61.1306 | 0.0003 | 23.4451 | 159.6830 | AID743067 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 55.8430 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 89.1251 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ORF73 | Human gammaherpesvirus 8 | EC50 (µMol) | 75.0000 | 0.0600 | 8.1346 | 32.1400 | AID435023 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID126044 | Inhibition of Monoamine oxidase A (MAO A) in rat brain. | 1997 | Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16 | Selective inhibitors of monoamine oxidase. 4. SAR of tricyclic N-methylcarboxamides and congeners binding at the tricyclics' hydrophilic binding site. |
| AID127026 | Inhibition of Monoamine oxidase B (MAO B) in rat brain at 0.3 uM | 1997 | Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16 | Selective inhibitors of monoamine oxidase. 4. SAR of tricyclic N-methylcarboxamides and congeners binding at the tricyclics' hydrophilic binding site. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (29.41) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.28) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||